Form 4: Electromed Director Fluet Receives 3,000 Restricted Shares

Electromed, Inc. Director Gregory Fluet was granted 3,000 shares of restricted common stock, scheduled to vest on June 1, 2026.

Summary

• Director Gregory Fluet of Electromed, Inc. acquired 3,000 shares of common stock.
• The transaction occurred on December 1, 2025.
• These shares are restricted stock, granted at a price of $0.
• The restricted stock is scheduled to vest on June 1, 2026, unless earlier accelerated or terminated.
• Following this transaction, Gregory Fluet beneficially owns 21,000 shares of Electromed, Inc. common stock.

Sentiment

Score: 6

Explanation: The filing reports a standard compensation event (restricted stock grant) for a director, which is generally a neutral to slightly positive signal as it aligns insider interests with long-term company performance. No significant positive or negative financial news is contained.

Positives

• A director receiving restricted stock aligns their interests with long-term shareholder value.
• The grant of 3,000 shares at a $0 price indicates a compensation component, potentially incentivizing performance and retention.

Risks

• The vesting of restricted stock is contingent on continued service and potentially performance, meaning the shares could be forfeited if terms are not met.

Future Outlook

The restricted stock grant with a future vesting date of June 1, 2026, indicates an expectation of continued service and alignment of the director's interests with the company's long-term performance.

Industry Context

Stock grants to directors are a common practice in publicly traded companies across various industries, including medical devices, to align director incentives with shareholder interests and retain talent.

Comparison to Industry Standards

• Granting restricted stock to directors is a standard compensation practice in many industries, including medical technology, to incentivize long-term commitment and performance.
• The specific number of shares (3,000) and the vesting schedule (approximately 6 months from the transaction date) would typically be evaluated against peer companies in the medical device sector to assess if it's within typical ranges for director compensation.

Related Party Transactions

• The grant of restricted stock to a director is a related party transaction, which is a standard compensation practice disclosed via Form 4.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with long-term shareholder value, with minimal dilution from these shares.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• The restricted stock will vest on June 1, 2026, assuming the terms of the grant are met.

Key Dates

Recommendation

This Form 4 reports a routine restricted stock grant to a director, which is a standard compensation practice. It does not contain information that would fundamentally alter the investment thesis for Electromed, Inc. Therefore, a 'hold' recommendation is appropriate as it doesn't present new reasons to buy or sell based solely on this filing.

Keywords

Electromed, ELMD, Form 4, Insider Trading, Restricted Stock, Stock Grant, Director Compensation, Beneficial Ownership